Treatment success rate for patients treated for MDR-TB in Americas (WHO region)
Americas (WHO region): Treatment success rate for patients treated for MDR-TB was 60.0% in 2022. ▲ Rising
Treatment success rate for patients treated for MDR-TB in Americas (WHO region), 2002–2022
Source: World Health Organization, Global Health Observatory.
Analysis
In 2022, treatment success rate for patients treated for mdr-tb in Americas (WHO region) stood at 60.0%.
The figure is down 3.2% on the previous year and up 5.3% over ten years.
Over the whole period, treatment success rate for patients treated for mdr-tb in Americas (WHO region) peaked at 62.0% in 2021 and was at its lowest, 38.0%, in 2007.
The long-run direction has been consistently rising across the 20 years of available data.
Treatment success rate for patients treated for MDR-TB in Americas (WHO region), year by year
| Year | Value | Change |
|---|---|---|
| 2002 | 53.0% | — |
| 2003 | 59.0% | +11.3% |
| 2004 | 60.0% | +1.7% |
| 2006 | 58.0% | -3.3% |
| 2007 | 38.0% | -34.5% |
| 2008 | 47.0% | +23.7% |
| 2009 | 47.0% | +0.0% |
| 2010 | 59.0% | +25.5% |
| 2011 | 56.0% | -5.1% |
| 2012 | 57.0% | +1.8% |
| 2013 | 55.0% | -3.5% |
| 2014 | 54.0% | -1.8% |
| 2015 | 56.0% | +3.7% |
| 2016 | 59.0% | +5.4% |
| 2017 | 60.0% | +1.7% |
| 2018 | 59.0% | -1.7% |
| 2019 | 59.0% | +0.0% |
| 2020 | 60.0% | +1.7% |
| 2021 | 62.0% | +3.3% |
| 2022 | 60.0% | -3.2% |
Biggest year-on-year movements
Years where Treatment success rate for patients treated for MDR-TB in Americas (WHO region) changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.
| Year | Change | From | To |
|---|---|---|---|
| 2007 | -34.5% | 58.0% | 38.0% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 51.7% | 38.0% | 60.0% | 7 |
| 2010s | 57.4% | 54.0% | 60.0% | 10 |
| 2020s | 60.7% | 60.0% | 62.0% | 3 |
More health data for Americas (WHO region)
- Pertussis - number of reported cases, gaps filled 24,640 (2025)
- Total tetanus - number of reported cases, gaps filled 385 (2025)
- Neonatal tetanus - number of reported cases, gaps filled 23 (2025)
- Measles - number of reported cases, gaps filled 12,380 (2025)
- Diphtheria - number of reported cases, gaps filled 72 (2025)
- Number of under-five deaths, annual growth rate -2.83 % change on previous year (2024)
- Number of neonatal deaths, annual growth rate -3.22 % change on previous year (2024)
- Number of infant deaths, annual growth rate -2.68 % change on previous year (2024)
- Measles - number of reported cases, annual growth rate 22.22 % change on previous year (2024)
- Pertussis - number of reported cases, annual growth rate -20.67 % change on previous year (2025)
Frequently asked questions
- What is treatment success rate for patients treated for mdr-tb in Americas (WHO region)?
- Treatment success rate for patients treated for mdr-tb in Americas (WHO region) was 60.0% in 2022, according to World Health Organization, Global Health Observatory.
- What is the highest treatment success rate for patients treated for mdr-tb recorded in Americas (WHO region)?
- The highest recorded value was 62.0% in 2021.
- What is the lowest treatment success rate for patients treated for mdr-tb recorded in Americas (WHO region)?
- The lowest recorded value was 38.0% in 2007.
- How does Americas (WHO region) rank for treatment success rate for patients treated for mdr-tb?
- Americas (WHO region) ranks 11th out of 11 groups with data for 2022.
- Is treatment success rate for patients treated for mdr-tb rising or falling in Americas (WHO region)?
- Over the last ten years it is up 5.3%. The long-run trend across the full record is rising.
- Where does this Americas (WHO region) data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Treatment success rate for patients treated for MDR-TB (%). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 20 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).